Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001123292-25-000298·Skorpios Trust
Schedule 13D ownership disclosure
Stoke Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 86150R107
Event date: 2025-06-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Blue Horizon Enterprise LtdReported CIK 0001869057
Shares: 2,967,621 · Class: 5.4%
- Ezbon International LtdReported CIK 0001869027
Shares: 288,560 · Class: 0.5%
- Montrago Trustees LtdReported CIK 0001869331
Shares: 3,256,181 · Class: 6%
- Skorpios TrustReported CIK 0001869333
Shares: 3,256,181 · Class: 6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001123292-25-000298
- Form type
- SCHEDULE 13D/A
- Filer
- Skorpios Trust
- CIK
- CIK 1869333
- Filed
- Jun 23, 2025
- Reporting period
- Jun 18, 2025
- Description
- Schedule 13D beneficial ownership